Who Owns Latigo Biotherapeutics Stock?
NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 86.17%
- Held by insiders
- 6.00%
- Institutional holders
- 61
- Institutions 86.2%
- Insiders 6.0%
- Public and other 7.8%
Who owns Latigo Biotherapeutics stock?
Institutional investors own about 86.2% of Latigo Biotherapeutics's shares, spread across 61 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.00% of LTGO.
The largest institutional holders are 5AM Venture Management, LLC (11.05%), RA Capital Management, L.P. (8.00%) and Deep Track Capital, Lp (6.65%). Together, the top 10 institutions control 50.8% of shares outstanding. In their latest filings, 10 of the top 10 institutions increased their LTGO positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of LTGO
| Institution | Shares | % Held | Change |
|---|---|---|---|
| 5AM Venture Management, LLC | 7.33M | 11.05% | +100.0% |
| RA Capital Management, L.P. | 5.30M | 8.00% | +100.0% |
| Deep Track Capital, Lp | 4.41M | 6.65% | +100.0% |
| Blue Owl Capital Holdings LP | 3.60M | 5.43% | +100.0% |
| Foresite Capital Management V, LLC | 3.56M | 5.37% | +100.0% |
| FMR, LLC | 2.88M | 4.34% | +100.0% |
| Foresite Capital Management VI LLC | 2.20M | 3.32% | +100.0% |
| Cormorant Asset Management, LP | 1.82M | 2.74% | +100.0% |
| Orbimed Advisors LLC. | 1.68M | 2.53% | +100.0% |
| Aberdeen Group plc | 935.72K | 1.41% | +100.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of LTGO
| Fund | Shares | % Held |
|---|---|---|
| Fidelity Contrafund | 868.07K | 1.31% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 526.70K | 0.79% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 212.50K | 0.32% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 191.40K | 0.29% |
| Fidelity Contrafund-Fidelity Contrafund K6 | 184.21K | 0.28% |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 105.20K | 0.16% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 88.70K | 0.13% |
| Fidelity Concord Street Trust-Fidelity Small Cap Discovery Fund | 69.60K | 0.10% |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 64.97K | 0.10% |
| Fidelity Concord Street Trust-Fidelity Series Small Cap Discovery Fund | 60.00K | 0.09% |
Frequently asked questions
Who is the largest shareholder of Latigo Biotherapeutics?
5AM Venture Management, LLC is the largest institutional shareholder of LTGO, owning 11.05% of shares outstanding (7.33M shares) as of its latest 13F filing.
What percentage of Latigo Biotherapeutics is owned by institutions?
Institutions own about 86.2% of LTGO shares and 91.7% of the public float.
How much of Latigo Biotherapeutics do insiders own?
Insiders, such as officers and directors, own about 6.00% of LTGO shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.